Core Viewpoint - The company has made a prudent decision to adjust the timeline for certain fundraising projects to reach their intended usable state, ensuring that this will not negatively impact the implementation of these projects or the interests of shareholders, particularly minority shareholders [1][2]. Group 1 - The second meeting of the supervisory board was convened on June 26, 2025, with all three supervisors present, and the meeting followed the required legal and procedural guidelines [1]. - The supervisory board unanimously approved the proposal to adjust the timeline for certain fundraising projects, with all votes in favor [1][2]. - The adjustment is based on the actual progress and feasibility of the projects, and it is confirmed that this decision will not adversely affect the company's operations or the interests of shareholders [2].

Group 1 - The company held its fourth supervisory board's second temporary meeting on June 20, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved a proposal to adjust the internal investment structure of certain fundraising projects and to use self-owned funds to pay for R&D personnel costs, replacing them with equivalent fundraising [1][2] - The supervisory board believes that the adjustment is a prudent decision based on the actual situation of the projects, optimizing resource allocation without harming the company's or shareholders' interests [1][2] Group 2 - The decision to use self-owned funds for certain payments is expected to improve operational efficiency, enhance capital turnover, and reduce financial costs [1] - The adjustments comply with the Shanghai Stock Exchange's regulations and the company's fundraising management system, ensuring no significant adverse impact on the fundraising projects [1][2] - The voting results showed unanimous support with 3 votes in favor, 0 against, and 0 abstentions [2]

Group 1 - The company held its 28th meeting of the second board on June 16, 2025, with all 11 directors present, and the meeting was conducted in accordance with relevant regulations [2][4] - The board approved several resolutions, including adjustments to the proposed investment amounts for fundraising projects, which do not require shareholder meeting approval [3][5][7] - The company plans to hold its second extraordinary general meeting of 2025 on July 2, 2025, to discuss various matters [11][12] Group 2 - The supervisory board also convened on June 16, 2025, with all three supervisors present, and approved similar resolutions regarding the adjustment of fundraising project amounts [13][15] - The supervisory board confirmed that the adjustments would not adversely affect the normal use of the raised funds and comply with relevant laws [14][18] Group 3 - The company announced the adjustment of the proposed investment amounts for fundraising projects, stating that the actual net fundraising amount was RMB 632,767,998.06 after deducting issuance costs [23][24] - The adjustments were made to ensure the smooth implementation of fundraising projects without changing the intended use of the funds [26][28] Group 4 - The company plans to use RMB 455,452,145.79 of the raised funds to replace pre-invested self-raised funds for fundraising projects and to cover issuance costs [34][36] - The company has established a special account for the management of raised funds to protect investor interests [24][35] Group 5 - The company will change its registered capital from RMB 280 million to RMB 325 million following the issuance of new shares [41][42] - The amendments to the company's articles of association will be submitted for shareholder approval [42] Group 6 - The company has scheduled its second extraordinary general meeting for July 2, 2025, with provisions for both on-site and online voting [45][46] - The meeting will address various resolutions that have already been approved by the board and supervisory board [47]

Group 1 - The company held its eighth board meeting, with all seven directors present, including three via telecommunication [1] - The board approved a proposal to adjust the internal investment structure and postpone project timelines, stating that the feasibility of the fundraising projects remains unchanged and will not adversely affect the company's operations [1] - The proposal received unanimous support with 7 votes in favor, and it will be submitted for shareholder meeting approval [2] Group 2 - The board approved a revision of the company's articles of association and will proceed with the necessary business registration changes [2] - The proposal to revise the articles received unanimous support with 7 votes in favor and will also be submitted for shareholder meeting approval [2] - The company plans to revise eight internal governance documents to enhance its corporate governance structure [5] Group 3 - The board proposed to convene the third extraordinary general meeting of shareholders in 2025 on June 27 [6] - The proposal for the meeting received unanimous support with 7 votes in favor [6]

Core Viewpoint - The company plans to terminate a fundraising project related to the production of semiconductor testing equipment and will manage the remaining funds in a dedicated account while seeking new investment opportunities [5][11]. Meeting Details - The first extraordinary general meeting of shareholders for 2025 is scheduled for June 16, 2025, in Shanghai, with registration from 14:00 to 14:30 and the meeting starting at 14:30 [1]. - Shareholders registered by June 10, 2025, are eligible to attend and vote, either in person or by proxy [1][4]. Agenda Items - The meeting will include the election of vote counters and monitors, discussion of the termination of certain fundraising projects, and a vote on the proposed resolutions [2][3]. - The main resolution involves terminating the project for producing 1,000 sets of semiconductor testing machine components and managing the remaining funds accordingly [3][12]. Fundraising Project Overview - The company raised approximately 746.81 million yuan from a public offering in February 2023, with the funds intended for various projects [5][6]. - As of May 19, 2025, the company had invested 78.61 million yuan in the terminated project, which was initially planned to enhance production capacity for semiconductor testing equipment [6][8]. Reasons for Project Termination - The decision to terminate the project is based on slower-than-expected progress due to external economic factors and challenges in supplier negotiations [7][10]. - The company aims to strengthen its supply chain management and improve cost efficiency by shifting to external suppliers for component production [9][11]. Future Fund Management - Remaining funds will continue to be stored in a dedicated account, with the company planning to explore new investment projects that align with its strategic goals [11][12]. - The company emphasizes that this decision is in line with its operational needs and will not harm shareholder interests [11][12].

Summary of Key Points Core Viewpoint The company is adjusting part of its fundraising projects and changing the use of some raised funds to optimize resource allocation and enhance operational efficiency, which aligns with its strategic development goals and benefits all shareholders [21][22]. Group 1: Fundraising Overview - The company has received approval from the China Securities Regulatory Commission for its initial public offering, raising a total of RMB 340.24 million by issuing 16.11 million shares at RMB 21.12 each [1]. - The funds are stored in a dedicated account, and a tripartite supervision agreement has been signed with the sponsor and the supervising bank [2]. Group 2: Actual Use of Funds - As of May 23, 2025, the company has invested RMB 39.84 million in various projects, with a remaining balance of RMB 11.02 million in unutilized funds [3][5]. - The main projects include the construction of an environmentally friendly water-based printing glue production base and a headquarters and R&D center [3]. Group 3: Adjustments to Fundraising Projects - The company plans to relocate its R&D center to an existing production base to improve management and reduce operational costs while maintaining the same investment amount [6][7]. - The adjustment aims to enhance collaboration between production and R&D, supporting the development of high-performance silicon-based materials [6][7]. Group 4: Changes in Project Investment - The company is merging two projects into one, increasing the annual production capacity from 15,000 tons to 27,750 tons for environmentally friendly water-based printing glue [8][9]. - The total investment for the merged project is set at RMB 20.83 million, with a proposed fundraising amount that matches the previous projects' total [9][10]. Group 5: Economic Benefits and Feasibility - The merged project is expected to generate an average annual sales revenue of RMB 37.72 million, with a financial internal rate of return of 13.75% and a net present value of RMB 2.68 million [12][14]. - The project aligns with national policies promoting green and sustainable development, enhancing the company's competitive edge in the market [15][16]. Group 6: Approval and Compliance - The adjustments have been approved by both the board of directors and the supervisory board, ensuring compliance with relevant regulations and guidelines [21][22]. - The sponsor has confirmed that the adjustments will not harm the interests of the company or its minority shareholders and will not adversely affect current operations [22].

Core Viewpoint - Nanjing New Pharmaceutical Co., Ltd. has announced multiple delays in its fundraising projects, particularly the "Marketing Channel Network Upgrade Project," which has been postponed to December 31, 2026, indicating ongoing challenges in project execution and market competition [1][3][4]. Group 1: Project Delays - The "Marketing Channel Network Upgrade Project" was initially set to be operational by June 30, 2025, but has now been delayed by an additional 18 months [1][3]. - The project aims to establish 8 new offices and upgrade 22 existing ones, with a total investment of 120 million yuan [2]. - The delays are attributed to macroeconomic conditions, industry policies, and a reduced need for new offices due to strategic adjustments [3][4]. Group 2: Termination of Projects - The company has terminated the "Palivizumab Dry Powder Inhalation Project" and redirected the remaining funds of 43.97 million yuan to the "Palivizumab Inhalation Solution Project" [4][5]. - The "Palivizumab Inhalation Solution Project" has also been delayed to December 31, 2026, with an increased funding allocation of 214 million yuan [4][6]. Group 3: Financial Performance - Nanjing New Pharmaceutical has faced significant financial challenges, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, representing a decrease of over 70% [8]. - The company has reported net losses in all years since its IPO, except for the first year, with a net profit of 128 million yuan in 2020 turning into a loss of 357 million yuan in 2024 [8]. - In Q1 2025, the company reported a revenue drop of 70.21% year-on-year, primarily due to lower market demand for antiviral products and price reductions [8]. Group 4: Market Strategy - The company has adopted a price reduction strategy to maintain market share in the competitive antiviral market, with a 43.51% price cut on its core product, Palivizumab, in 2023 [7]. - Despite these efforts, the declining sales and increased competition have not improved the company's financial situation [7][8].

国金证券股份有限公司（以下简称"保荐机构"）为立达信物联科技股份有 限公司（以下简称"立达信"或"公司"）首次公开发行股票并上市的保荐机构， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》《上市公司监管指引第2号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第1号——规范运作》等有关规定，对立达信将部分 募投项目节余募集资金用于其他募投项目及部分募投项目延期的事项进行了核 查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额及到位时间 经中国证券监督管理委员会《关于核准立达信物联科技股份有限公司首次公 开发行股票的批复》 （证监许可〔2021〕2186 号）核准，公司向社会公开发行人 民币普通股（A 股）5,000 万股，每股面值为人民币 1.00 元，发行价格为人民币 万元（不含增值税）后，实际募集资金净额为人民币 77,135.33 万元。 国金证券股份有限公司关于立达信物联科技股份有限公司 将部分募投项目节余募集资金用于其他募投项目及部分募投项 目延期的核查意见 前述 ...

天洋新材（上海）科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 天洋新材（上海）科技股份有限公司（以下简称"公司"）第四届监事会第二十五 次会议于 2025 年 05 月 26 日上午 11 时在公司二楼会议室以现场方式召开，本次会议应 出席监事 3 人，现场实际出席监事 3 人，董事会秘书及证券事务代表列席了本次会议。 会议由公司监事会主席郑晓燕女士主持。本次会议的召开符合《中华人民共和国公司法》 （以下简称"《公司法》"）、《天洋新材（上海）科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，会议合法、有效。 二、 监事会会议审议情况 （一）审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》 证券代码：603330 证券简称：天洋新材 公告编号：2025-042 易所上市公司自律监管指引第 1 号——规范运作》等有关规定，结合 2022 年度非公开发 行募集资金投资项目的资金使用计划和项目的建设进度，公司在确保不影响募集资金投 资项目建设的前提下，为提高 ...

Core Viewpoint - The company has announced adjustments to its fundraising projects, including changes in investment amounts and the addition of new implementation entities, which are expected to be normal adjustments based on existing resources and market conditions [1][4]. Group 1: Project Adjustments - The total investment for the "Machining Expansion and Component Industry Chain Extension Project" has increased from 56,437.53 thousand yuan to 78,511.92 thousand yuan, with an additional investment of 22,074.39 thousand yuan funded entirely by the company's own funds [2]. - The company will reallocate 1,500.00 thousand yuan of raised funds from the "Intelligent Upgrade of Casting Production Line and R&D Capability Enhancement Project" to the "Machining Expansion and Component Industry Chain Extension Project," supplemented by 1,500.00 thousand yuan from its own funds [2]. - New implementation entities, including Huaxiang Saint Dema (Shanghai) and its wholly-owned subsidiary Huaxiang Automotive Technology Company, will be added alongside existing entities for the execution of the fundraising projects [2]. Group 2: Bond Redemption and Rating - The adjustments have triggered additional redemption clauses for the "Huaxiang Convertible Bonds," allowing bondholders to choose whether to redeem their bonds at a price of 100.58 yuan per bond during the redemption period from May 12 to May 16, 2025 [2][3]. - The company has decided to exercise its right to early redemption of the "Huaxiang Convertible Bonds" due to the stock price meeting the conditions for conditional redemption [3]. - The credit rating agency maintains the company's credit rating at AA- and the outlook at AA-, while closely monitoring the use of raised funds and the progress of the fundraising projects [4].